Advocates told Georgia lawmakers at Mercer University that strict limits on the state's medical cannabis program block thousands with chronic illnesses from legal relief. The 2019 Hope Act confines eligibility to terminal conditions and mandates non-smokable products from just three licensed dispensaries. With only about 30,000 enrolled patients according to the Georgia Department of Public Health, speakers argued these barriers drive people to illegal markets or neighboring states.
Outdated Rules Limit Patient Reach
Georgia's Low-THC Medical Cannabis Program requires a diagnosis of a terminal illness for participation, a threshold that excludes many with persistent pain or other debilitating conditions. Patients must obtain oils, pills, lotions, or patches solely from state-approved outlets like Fine Fettle in Macon, one of three operators. This setup, while ensuring regulated quality, restricts supply and form factors, preventing inhalable options that advocates say deliver faster symptom control for conditions such as severe nausea or acute pain.
Dispensary Leaders and Lawmakers Weigh In
Judson Hill, Georgia Market President for Fine Fettle, urged expansion to more products and qualifying ailments during Thursday's hearing. He emphasized locally grown, tested cannabis as a safe alternative already available but underutilized. State Rep. Mark Newton, a physician chairing the House Blue Ribbon Study Committee on Medical Marijuana and Hemp Policies, supports wider access yet stresses safeguards for youth, calling for precise medical guidelines to match treatments to needs.
Legislative Momentum Builds Amid Setbacks
The committee tours Georgia to gather testimony, aiming for 2026 recommendations after expansion bills stalled in both legislative chambers this year. Critics of the status quo point to patients crossing state lines or turning to unregulated sources, undermining public health goals. Broader access could align Georgia with evolving national trends where medical cannabis treats diverse conditions, potentially reducing reliance on opioids while maintaining strict oversight on potency and youth protections.
